Tolerability of High-Dose Aripiprazole in Treatment-Refractory Schizophrenic Patients

View This PDF

NB: This article is only available as a PDF.

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Aripiprazole is a new antipsychotic that works as a partial agonist/antagonist at dopamine D2 and serotonin 5-HT1A receptors and has a favorable side effect profile.1 The maximum manufacturer-recommended dose in the United States is 30 mg/day, although patients with a history of antipsychotic nonresponse are likely to be treated with aripiprazole doses over 30 mg. Review of the literature found 1 safety study of 40 patients with stable schizophrenia or schizoaffective disorder who were administered aripiprazole 30 to 90 mg with no dose-dependent increases of adverse events.2

J Clin Psychiatry 2006;67(7):1158-1159